Entera Bio Valuation
| ENTXWDelisted Stock | USD 0 0.00 0.00% |
Entera Bio seems to be overvalued based on Macroaxis valuation methodology. Our model computes the value of Entera Bio from reviewing the firm fundamentals such as EBITDA of (13.02 M), total debt of 91 K, and Retained Earnings of (95.5 M) as well as analyzing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Entera Bio's price fluctuation is very steady at this time. Calculation of the real value of Entera Bio is based on 3 months time horizon. Increasing Entera Bio's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Entera stock is determined by what a typical buyer is willing to pay for full or partial control of Entera Bio. Since Entera Bio is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Entera Stock. However, Entera Bio's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.0012 | Real 0.00114 | Hype 0.0015 | Naive 0.011 |
The intrinsic value of Entera Bio's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Entera Bio's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Entera Bio helps investors to forecast how Entera stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Entera Bio more accurately as focusing exclusively on Entera Bio's fundamentals will not take into account other important factors: Entera Bio Total Value Analysis
Entera Bio is currently anticipated to have takeover price of 0 with market capitalization of 0, debt of 91 K, and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Entera Bio fundamentals before making investing decisions based on enterprise value of the companyEntera Bio Asset Utilization
The concept of asset utilization usually refers to the revenue earned for every dollar of assets a company currently reports. The latest return on assets of Entera indicates not a very effective usage of assets in February.Entera Bio Profitability Analysis
The company reported the revenue of 134 K. Net Loss for the year was (13.07 M) with profit before overhead, payroll, taxes, and interest of 0.About Entera Bio Valuation
Our relative valuation model uses a comparative analysis of Entera Bio. We calculate exposure to Entera Bio's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Entera Bio's related companies.Entera Bio Growth Indicators
Investing in growth stocks can be very risky. If the company such as Entera Bio does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 28.8 M |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Other Consideration for investing in Entera Stock
If you are still planning to invest in Entera Bio check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Entera Bio's history and understand the potential risks before investing.
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Stocks Directory Find actively traded stocks across global markets | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |